



US 20200297862A1

(19) **United States**(12) **Patent Application Publication**
Ng(10) **Pub. No.: US 2020/0297862 A1**(43) **Pub. Date: Sep. 24, 2020**(54) **METHODS OF USING BISPECIFIC
ANTIGEN-BINDING CONSTRUCTS
TARGETING HER2***A61K 39/395* (2006.01)*A61K 45/06* (2006.01)*A61P 35/00* (2006.01)(52) **U.S. Cl.**CPC *A61K 47/6811* (2017.08); *A61K 47/65*
(2017.08); *A61P 35/00* (2018.01); *A61K 45/06*
(2013.01); *A61K 39/3955* (2013.01)(71) Applicant: **Zymeworks Inc.**, Vancouver (CA)(72) Inventor: **Gordon Yiu Kon Ng**, Vancouver (CA)(21) Appl. No.: **16/088,761**(22) PCT Filed: **Apr. 25, 2017**(86) PCT No.: **PCT/CA2017/050507**

§ 371 (c)(1),

(2) Date: **Sep. 26, 2018****Related U.S. Application Data**(60) Provisional application No. 62/327,304, filed on Apr.
25, 2016.**Publication Classification**(51) **Int. Cl.***A61K 47/68* (2006.01)*A61K 47/65* (2006.01)(57) **ABSTRACT**

Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

Specification includes a Sequence Listing.